ClinicalTrials.gg
CompletedNCT04515784START-PTSDUpdated Nov 17, 2026Results posted

Safety Aid Reduction Treatment for PTSD Among Veterans

An interventional study of Safety Aid Reduction Treatment for PTSD in Stress Disorders, Post-Traumatic, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development — 56 open to participants now, 65 under way, 4 of them phase 3. Stress Disorders, Post-Traumatic · VA Office of Research and Development.

Enrollment
180th of 246
45 · median 87
Started
2023
with 13 others
No phase
185 of 263
42 open now
Registered
177th of 263
by date

Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 180th largest by enrollment of the 246 interventional ones that give a count, is one of 14 that started in 2023, is one of 185 with no phase, and was the 177th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

56 of the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 56 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

The purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (START) among Veterans with posttraumatic stress disorder (PTSD). It is hypothesized that START will be acceptable, feasible, and will lead to reductions in PTSD symptom severity immediately and over time.

Read the detailed description

Rates of posttraumatic stress disorder (PTSD) among military personnel have surged in recent years. In response, the Department of Veterans Affairs (VA) has launched nationwide training initiatives to disseminate two PTSD treatments with strong empirical support: prolonged exposure (PE) therapy and cognitive processing therapy (CPT). Despite the well-documented effectiveness of PE and CPT, only a minority of Veterans with PTSD initiate these trauma-focused treatments. One approach to addressing PTSD in a non-trauma-focused fashion is to utilize empirically supported treatments focused on safety aid reduction. Safety aids are maladaptive cognitive and/or behavioral strategies designed to prevent, avoid, or alleviate anxiety. Initially introduced as a way to explain how pathological anxiety can persist despite repeated exposure to feared stimuli, safety aids have been found to play a critical role in the etiology and maintenance of various anxiety and related conditions including PTSD. Importantly, a separate line of research suggests that safety aids are amenable to change through cognitive behavioral interventions. Although promising, these trials did not include patients with PTSD. In this context, the purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (START) for PTSD. Participants will include veterans with a diagnosis of PTSD who decline to participate in evidence-based psychotherapies (EBPs) for PTSD, namely PE or CPT. It is hypothesized that START will be acceptable, feasible, and will lead to reductions in PTSD symptom severity immediately and over time.

03

Conditions studied

  • Stress Disorders, Post-Traumatic

Keywords

  • Safety aid
  • Treatment
  • Posttraumatic Stress Disorder
  • Veteran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans receiving care at New Orleans VA
  • Veterans with diagnosis of PTSD who decline trauma focused treatment

Exclusion criteria

Exclusion Criteria:

  • Substance dependence requiring detoxification
  • Active psychosis
  • Uncontrolled Bipolar Disorder
  • Severe suicidal intent requiring hospitalization
  • Current engagement in psychotherapy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Active

    Active arm- START-PTSD

    Behavioral: Safety Aid Reduction Treatment for PTSD

Interventions

  • BehavioralSafety Aid Reduction Treatment for PTSD

    START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).

06

What researchers measure

Primary outcomes

  1. Change in PTSD Diagnostic Status as Measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

    The CAPS-5 is a 30-item clinician-administered interview designed to assess current (i.e., past month) and lifetime PTSD diagnostic status. In addition to assessing the 20 DSM-5 PTSD symptoms, the CAPS-5 contains questions regarding the onset and duration of symptoms, associated impairment in various life domains, and specifications for the dissociative subtype. The past month CAPS-5 will be administered at baseline and one-month follow-up to assess changes in PTSD diagnostic status. Totals scores range 0-80, where higher scores indicating higher symptom severity.

    Time frame: One-month follow-up

  2. Change in PTSD Symptoms as Measured by the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-report questionnaire designed to assess each of the 20 DSM-5 PTSD symptoms. Veterans will be asked to read a list of symptoms and indicate their level of distress as it relates to each within the past month using a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (Extremely). Total scores can range from 0 to 80 with higher scores reflecting increased symptom severity. The PCL-5 will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD symptom severity.

    Time frame: Post-intervention (10-weeks) and one-month follow-up

  3. Changes in Safety Aid Usage as Measured by the Safety Behavior Assessment Form (SBAF)

    The SBAF is a 41-item self-report questionnaire designed to assess safety behavior usage. Veterans will be asked to read a list of behaviors and rate how often they engage in each behavior using a 4-point Likert-type scale ranging from 0 (Never) to 3 (Always). Total scores can range from 0 to 123 with higher scores reflecting increased symptom severity. The SBAF will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in safety behavior usage.

    Time frame: Post-intervention (10-weeks) and one-month follow-up

  4. Client Satisfaction Questionnaire-8 (CSQ-8)

    The CSQ-8 is an 8-item self-report questionnaire designed to assess overall satisfaction with treatment services. Although response options differ from item-to-item, all questions are rated on a 4-point Likert-type scale ranging from 1 to 4 (total scores ranging 8 - 32) with higher scores indicating higher treatment satisfaction. The CSQ-8 will be administered immediately following the 10-week group to assess treatment acceptability.

    Time frame: Post-intervention (10-weeks)

Secondary outcomes

  1. Changes in Anxiety as Measured by the Beck Anxiety Inventory (BAI)

    The BAI is a 21-item self-report questionnaire designed to assess the experience of anxiety symptoms. Veterans will be asked to rate how often they experience each symptom using a 4-point Likert-type scale ranging from 0 (Not at all) to 3 (Severely). Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BAI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in anxiety symptoms.

    Time frame: Post-intervention (10-weeks) and one-month follow-up

  2. Changes in Depression as Measured by the Beck Depression Inventory-II (BDI-II)

    The BDI-II is a 21-item self-report questionnaire designed to assess symptoms associated with depression. Using a 4-point Likert-type scale ranging from 0 to 3, Veterans will be asked to select the statement from a group of statements that best represents how they have felt over the last two weeks. Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BDI-II will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in depression symptoms.

    Time frame: Post-intervention (10-weeks) and one-month follow-up

  3. Changes in PTSD Cognitions as Measured by the Posttraumatic Cognitions Inventory (PTCI)

    The PTCI is a 33-item self-report questionnaire designed to assess trauma-related thoughts and beliefs including negative cognitions regarding the self, others, and the world. Veterans will be asked to read a list of statements and indicate the degree to which they agree or disagree with each statement using a 7-point Likert-type scale ranging from 1(totally disagree) to 7 (totally agree). Total scores can range from 33 to 231 with higher scores reflecting increased symptom severity. The PTCI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD cognitions.

    Time frame: Post-intervention (10-weeks) and one-month follow-up

  4. Changes in Functional Impairment as Measured by the Sheehan Disability Scale (SDS)

    The SDS is a 3-item self-report questionnaire designed to assess functional impairment functional impairment in work/school, social, and family life. For each domain, Veterans will be asked to provide an impairment rating ranging from 0 (Not at all) to 10 (Extremely). Total scores can range from 0 to 30 with higher scores reflecting increased impairment. The SDS will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in functional impairment.

    Time frame: Post-intervention (10-weeks) and one-month follow-up

07

Results

Posted Oct 9, 2026

Participant flow

Veterans receiving care at the New Orleans VA were recruited over a two-year period from outpatient mental health. Specifically, Veterans with a diagnosis of PTSD who declined or prematurely dropped of trauma-focused treatment for PTSD were given information about the study and assessed for eligibility.

Participant flow — Overall Study
MilestoneActive Arm- START-PTSD
Started45
Completed31
Not completed14
Withdrew: Lost to follow-up7
Withdrew: Adverse event1
Withdrew: Withdrawal by subject6

Outcome measures

PrimaryChange in PTSD Diagnostic Status as Measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

The CAPS-5 is a 30-item clinician-administered interview designed to assess current (i.e., past month) and lifetime PTSD diagnostic status. In addition to assessing the 20 DSM-5 PTSD symptoms, the CAPS-5 contains questions regarding the onset and duration of symptoms, associated impairment in various life domains, and specifications for the dissociative subtype. The past month CAPS-5 will be administered at baseline and one-month follow-up to assess changes in PTSD diagnostic status. Totals scores range 0-80, where higher scores indicating higher symptom severity.

Time frame:
One-month follow-up
Reported as:
Mean · Score on a scale
Change in PTSD Diagnostic Status as Measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
Score on a scaleActive Arm- START-PTSD
Change in PTSD Diagnostic Status as Measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)27.89 ± 11.25
PrimaryChange in PTSD Symptoms as Measured by the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)

The PCL-5 is a 20-item self-report questionnaire designed to assess each of the 20 DSM-5 PTSD symptoms. Veterans will be asked to read a list of symptoms and indicate their level of distress as it relates to each within the past month using a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (Extremely). Total scores can range from 0 to 80 with higher scores reflecting increased symptom severity. The PCL-5 will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD symptom severity.

Time frame:
Post-intervention (10-weeks) and one-month follow-up
Reported as:
Mean · Score on a scale
Change in PTSD Symptoms as Measured by the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Score on a scaleActive Arm- START-PTSD
Post-intervention (10-weeks)50.03 ± 17.97
One-month follow-up50.04 ± 16.16
PrimaryChanges in Safety Aid Usage as Measured by the Safety Behavior Assessment Form (SBAF)

The SBAF is a 41-item self-report questionnaire designed to assess safety behavior usage. Veterans will be asked to read a list of behaviors and rate how often they engage in each behavior using a 4-point Likert-type scale ranging from 0 (Never) to 3 (Always). Total scores can range from 0 to 123 with higher scores reflecting increased symptom severity. The SBAF will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in safety behavior usage.

Time frame:
Post-intervention (10-weeks) and one-month follow-up
Reported as:
Mean · Score on a scale
Changes in Safety Aid Usage as Measured by the Safety Behavior Assessment Form (SBAF)
Score on a scaleActive Arm- START-PTSD
Post-intervention (10-weeks)67.10 ± 22.83
One-month follow-up63.85 ± 21.92
PrimaryClient Satisfaction Questionnaire-8 (CSQ-8)

The CSQ-8 is an 8-item self-report questionnaire designed to assess overall satisfaction with treatment services. Although response options differ from item-to-item, all questions are rated on a 4-point Likert-type scale ranging from 1 to 4 (total scores ranging 8 - 32) with higher scores indicating higher treatment satisfaction. The CSQ-8 will be administered immediately following the 10-week group to assess treatment acceptability.

Time frame:
Post-intervention (10-weeks)
Reported as:
Mean · Score on a scale
Client Satisfaction Questionnaire-8 (CSQ-8)
Score on a scaleActive Arm- START-PTSD
Client Satisfaction Questionnaire-8 (CSQ-8)27.55 ± 3.20
SecondaryChanges in Anxiety as Measured by the Beck Anxiety Inventory (BAI)

The BAI is a 21-item self-report questionnaire designed to assess the experience of anxiety symptoms. Veterans will be asked to rate how often they experience each symptom using a 4-point Likert-type scale ranging from 0 (Not at all) to 3 (Severely). Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BAI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in anxiety symptoms.

Time frame:
Post-intervention (10-weeks) and one-month follow-up
Reported as:
Mean · Score on a scale
Changes in Anxiety as Measured by the Beck Anxiety Inventory (BAI)
Score on a scaleActive Arm- START-PTSD
Post-intervention (10-weeks)24.29 ± 11.38
One-month follow-up27.11 ± 13.60
SecondaryChanges in Depression as Measured by the Beck Depression Inventory-II (BDI-II)

The BDI-II is a 21-item self-report questionnaire designed to assess symptoms associated with depression. Using a 4-point Likert-type scale ranging from 0 to 3, Veterans will be asked to select the statement from a group of statements that best represents how they have felt over the last two weeks. Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BDI-II will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in depression symptoms.

Time frame:
Post-intervention (10-weeks) and one-month follow-up
Reported as:
Mean · Score on a scale
Changes in Depression as Measured by the Beck Depression Inventory-II (BDI-II)
Score on a scaleActive Arm- START-PTSD
Post-intervention (10-weeks)24.73 ± 13.81
One-month follow-up30.37 ± 15.74
SecondaryChanges in PTSD Cognitions as Measured by the Posttraumatic Cognitions Inventory (PTCI)

The PTCI is a 33-item self-report questionnaire designed to assess trauma-related thoughts and beliefs including negative cognitions regarding the self, others, and the world. Veterans will be asked to read a list of statements and indicate the degree to which they agree or disagree with each statement using a 7-point Likert-type scale ranging from 1(totally disagree) to 7 (totally agree). Total scores can range from 33 to 231 with higher scores reflecting increased symptom severity. The PTCI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD cognitions.

Time frame:
Post-intervention (10-weeks) and one-month follow-up
Reported as:
Mean · Score on a scale
Changes in PTSD Cognitions as Measured by the Posttraumatic Cognitions Inventory (PTCI)
Score on a scaleActive Arm- START-PTSD
Post-intervention (10-weeks)134.37 ± 42.14
One-month follow-up144.07 ± 46.64
SecondaryChanges in Functional Impairment as Measured by the Sheehan Disability Scale (SDS)

The SDS is a 3-item self-report questionnaire designed to assess functional impairment functional impairment in work/school, social, and family life. For each domain, Veterans will be asked to provide an impairment rating ranging from 0 (Not at all) to 10 (Extremely). Total scores can range from 0 to 30 with higher scores reflecting increased impairment. The SDS will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in functional impairment.

Time frame:
Post-intervention (10-weeks) and one-month follow-up
Reported as:
Mean · Score on a scale
Changes in Functional Impairment as Measured by the Sheehan Disability Scale (SDS)
Score on a scaleActive Arm- START-PTSD
Post-intervention (10-weeks)20.06 ± 6.02
One-month follow-up19.67 ± 7.03

Adverse events

Collected over From enrollment until the end of the one-month follow-up (4-months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Arm- START-PTSD0/45 (0%)4/45 (8.9%)0/45 (0%)
Most frequent serious events
Most frequent serious events
EventActive Arm- START-PTSD
Suicidal ideationPsychiatric disorders3/45
Suicide attemptPsychiatric disorders1/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Active Arm- START-PTSD
Mean50.20 ± 13.07
Sex: Female, Male
Sex: Female, Male(Participants)Active Arm- START-PTSD
Female14
Male31
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active Arm- START-PTSD
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American26
White15
More than one race3
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Arm- START-PTSD
Hispanic or Latino2
Not Hispanic or Latino43
Unknown or Not Reported0
Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
Clinician Administered PTSD Scale for DSM-5 (CAPS-5)(Score on a scale)Active Arm- START-PTSD
Mean37.93 ± 9.60
PTSD Checklist for DSM-5 (PCL-5)
PTSD Checklist for DSM-5 (PCL-5)(Score on a scale)Active Arm- START-PTSD
Mean58.91 ± 13.25
Safety Behavior Assessment Form (SBAF)
Safety Behavior Assessment Form (SBAF)(Score on a scale)Active Arm- START-PTSD
Median74.37 ± 18.09
Beck Anxiety Inventory (BAI)
Beck Anxiety Inventory (BAI)(Score on a scale)Active Arm- START-PTSD
Mean32.36 ± 13.42

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Southeast Louisiana Veterans Health Care System, New Orleans, LA
    New Orleans, Louisiana 70119, United States
09

References and documents

Publications

  • Rosen CS, Bernardy NC, Chard KM, Clothier B, Cook JM, Crowley J, Eftekhari A, Kehle-Forbes SM, Mohr DC, Noorbaloochi S, Orazem RJ, Ruzek JI, Schnurr PP, Smith BN, Sayer NA. Which patients initiate cognitive processing therapy and prolonged exposure in department of veterans affairs PTSD clinics? J Anxiety Disord. 2019 Mar;62:53-60. doi: 10.1016/j.janxdis.2018.11.003. Epub 2018 Nov 20. PubMed 30550959 ↗
  • Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010 Aug;30(6):635-41. doi: 10.1016/j.cpr.2010.04.007. Epub 2010 May 2. PubMed 20546985 ↗
  • Dunmore E, Clark DM, Ehlers A. Cognitive factors involved in the onset and maintenance of posttraumatic stress disorder (PTSD) after physical or sexual assault. Behav Res Ther. 1999 Sep;37(9):809-29. doi: 10.1016/s0005-7967(98)00181-8. PubMed 10458046 ↗
  • Riccardi CJ, Korte KJ, Schmidt NB. False Safety Behavior Elimination Therapy: A randomized study of a brief individual transdiagnostic treatment for anxiety disorders. J Anxiety Disord. 2017 Mar;46:35-45. doi: 10.1016/j.janxdis.2016.06.003. Epub 2016 Jun 18. PubMed 27397584 ↗
  • Schmidt NB, Buckner JD, Pusser A, Woolaway-Bickel K, Preston JL, Norr A. Randomized controlled trial of false safety behavior elimination therapy: a unified cognitive behavioral treatment for anxiety psychopathology. Behav Ther. 2012 Sep;43(3):518-32. doi: 10.1016/j.beth.2012.02.004. Epub 2012 Mar 9. PubMed 22697441 ↗
  • Monson CM, Schnurr PP, Resick PA, Friedman MJ, Young-Xu Y, Stevens SP. Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. J Consult Clin Psychol. 2006 Oct;74(5):898-907. doi: 10.1037/0022-006X.74.5.898. PubMed 17032094 ↗
  • Fulton JJ, Calhoun PS, Wagner HR, Schry AR, Hair LP, Feeling N, Elbogen E, Beckham JC. The prevalence of posttraumatic stress disorder in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans: a meta-analysis. J Anxiety Disord. 2015 Apr;31:98-107. doi: 10.1016/j.janxdis.2015.02.003. Epub 2015 Feb 19. PubMed 25768399 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There are no plans to disclose data outside of the VA, however, if there is a need to disclose data outside of the VA (e.g., a member of the scientific community requests a copy), IRB approval will be sought, data will be de-identified prior to disclosing, and the disclosure will be recorded on a VA disclosure log as required by VA policy.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Sep 2025, 25 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 25 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

Start moved once since we started tracking on Sep 25, 2026: Sep 2024 → Aug 2023, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2020
First posted
Aug 17, 2020
StartActual
Aug 7, 2023was Sep 2024
Primary completionActual
Sep 29, 2025
CompletionActual
Sep 30, 2025
Results first posted
Oct 9, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 9, 2026 · revised Nov 17, 2026
Start date
Sep 23, 2024→Aug 7, 2023
Oct 9, 2026
Primary outcomes
3 edited, 1 description edited
What changed in the outcomes
  • EditedChange in PTSD diagnostic statusDiagnostic Status as measuredMeasured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)Time frame: Baseline and one-month follow-up → One-month follow-up
  • EditedChange in PTSD symptomsSymptoms as measuredMeasured by the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
  • EditedChanges in safety aid usageSafety Aid Usage as measuredMeasured by the Safety Behavior Assessment Form (SBAF)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
  • DescriptionClient Satisfaction Questionnaire-8 (CSQ-8): how it is measured was reworded
Oct 9, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 9, 2026
  • EditedChanges in anxietyAnxiety as measuredMeasured by the Beck Anxiety Inventory (BAI)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
  • EditedChanges in depressionDepression as measuredMeasured by the Beck Depression Inventory-II (BDI-II)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
  • EditedChanges in PTSD cognitionsCognitions as measuredMeasured by the Posttraumatic Cognitions Inventory (PTCI)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
  • EditedChanges in funtional impairmentFuntional Impairment as measuredMeasured by the Sheehan Disability Scale (SDS)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
What changed on Nov 17, 2026
  • EditedChanges in FuntionalFunctional Impairment as Measured by the Sheehan Disability Scale (SDS)Time frame: Post-intervention (10-weeks) and one-month follow-up
across 2 updates, Oct 9, 2026 – Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Posted results revised
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChanges in FuntionalFunctional Impairment as Measured by the Sheehan Disability Scale (SDS)Time frame: Post-intervention (10-weeks) and one-month follow-up
    + 1 other change: verification date
  2. Oct 9, 2026
    Results posted
    Start date Sep 23, 2024→Aug 7, 2023
    Primary outcomes 3 edited, 1 description edited
    What changed in the outcomes
    • EditedChange in PTSD diagnostic statusDiagnostic Status as measuredMeasured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)Time frame: Baseline and one-month follow-up → One-month follow-up
    • EditedChange in PTSD symptomsSymptoms as measuredMeasured by the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
    • EditedChanges in safety aid usageSafety Aid Usage as measuredMeasured by the Safety Behavior Assessment Form (SBAF)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
    • DescriptionClient Satisfaction Questionnaire-8 (CSQ-8): how it is measured was reworded
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedChanges in anxietyAnxiety as measuredMeasured by the Beck Anxiety Inventory (BAI)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
    • EditedChanges in depressionDepression as measuredMeasured by the Beck Depression Inventory-II (BDI-II)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
    • EditedChanges in PTSD cognitionsCognitions as measuredMeasured by the Posttraumatic Cognitions Inventory (PTCI)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
    • EditedChanges in funtional impairmentFuntional Impairment as measuredMeasured by the Sheehan Disability Scale (SDS)Time frame: Baseline, post-intervention (10-weeks), and one-month follow-up → Post-intervention (10-weeks) and one-month follow-up
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04515784
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Aug 7, 2023
Primary completion
Sep 29, 2025
Completion
Sep 30, 2025
Results posted
Oct 9, 2026
Last update
Nov 17, 2026

Study contacts

Amanda M Raines, PhD
principal investigator · Southeast Louisiana Veterans Health Care System, New Orleans, LA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion